glp 1 agonist crohn's disease Adjunctive GLP1 Receptor Agonists in Patients With Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation GLP-1s and Crohn's Disease: Safety,
Description
GLP-1s on their own have a low risk of hypoglycemia
The changes resulted in a decrease in serum GLP-1 along with insulin resistance and metabolic dysfunction
The most common side effects of dulaglutide are nausea, vomiting, and diarrhea
The LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial was a pivotal milestone as it showed the cardiovascular benefits of liraglutide in patients with T2D and high cardiovascular risk
Diabetologia 66 , 18461858 (2023)
These medications work by reducing appetite, improving blood sugar levels, and slowing down digestion, which helps you feel fuller for longer
